Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial
Methotrexat, Doxorubicin und Cisplatin versus Methotrexat, Doxorubicin und Cisplatin plus Ifosfamid bei schlechten Respondern auf eine präoperative Chemotherapie bei neu diagnostiziertem High-Grade-Osteosarkom (JCOG0905): multizentrische, offene, randomisierte Studie
Journal of Clinical Oncology · 2025-06 · 43 (16) · 1886-1897
DOI: 10.1200/jco-24-01281 ↗Auf einen Blick
Bei Patient:innen mit schlechtem Ansprechen auf MAP nach Operation zeigte die Zugabe von Ifosfamid keinen Vorteil im krankheitsfreien Überleben. Das Gesamtüberleben war numerisch schlechter in der MAPIF-Gruppe.
Fragestellung
Verbessert die Zugabe von Ifosfamid zu MAP bei schlechten Respondern mit neu diagnostiziertem High-Grade-Osteosarkom das krankheitsfreie Überleben?
Methode
Multizentrische, offene, randomisierte Studie bei Patient:innen mit resektablem High-Grade-Osteosarkom der Extremitäten, der Gliedergürtel und der Thoraxwand; Randomisierung nach zwei MAP-Zyklen und Tumorresektion.
Ergebnisse
51 Patient:innen erhielten MAP und 52 MAPIF. DFS: HR 1,05 (95 %-KI 0,55–1,98). OS: HR 1,48 (95 %-KI 0,68–3,22). Neun Patient:innen brachen in der MAPIF-Gruppe wegen UAW ab, keine in der MAP-Gruppe.
Schlussfolgerung der Autor:innen
Die Evidenz aus JCOG0905 unterstützt die Zugabe von Ifosfamid bei Patient:innen mit schlechtem Ansprechen nicht.
Kernaussagen
- Kein Unterschied im krankheitsfreien Überleben
- Gesamtüberleben numerisch schlechter unter MAPIF
- Behandlungsabbrüche nur in der MAPIF-Gruppe
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2025-06. Verfasst von Hiroaki Hiraga und 29 weiteren Autor:innen. Beteiligte Einrichtung: Musculoskeletal Oncology, NHO Hokkaido Cancer Center, Sapporo, Japan. Hauptthemen laut MEDLINE: Osteosarcoma, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2 once on day 1, then 2g/m 2 once on days 2-7] × six) to patients showing a poor response (PrRsp) to preoperative chemotherapy with methotrexate, doxorubicin, and cisplatin (MAP) improves their prognoses. In this Japan Clinical Oncology Group (JCOG) study, JCOG0905, we aimed to investigate the efficacy and safety of IF in patients with PrRsp. METHODS JCOG0905 is a multicenter, open-label, multi-institutional, randomized trial. Eligible patients (50 years and younger) had resectable, high-grade osteosarcoma (stage II or III, Union for International Cancer Control TNM) of the extremities, limb girdles, and thoracic wall. After two MAP cycles and tumor resection, patients with PrRsp were randomly assigned to either the MAP or MAP plus 15 g/m 2 (3g/m 2 once daily on days 1-5) × six IF (MAP + IF [MAPIF]) group. The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The planned sample size was 100 patients with a one-sided α of .1 and a power of 0.7, assuming a 3-year DFS of 50% and 65% for MAP and MAPIF, respectively. This trial is registered with the Japan Registry of Clinical Trials (jRCT; jRCTs031180126). RESULTS Of the 287 patients registered between February 2010 and August 2020, 51 and 52 patients with PrRsp were assigned to the MAP and MAPIF groups, respectively. As of March 2022, DFS did not differ between groups (hazard ratio [HR], 1.05 [95% CI, 0.55 to 1.98]) and OS was numerically inferior in the MAPIF group (HR, 1.48 [95% CI, 0.68 to 3.22]). Nine and zero patients in the MAPIF and MAP groups discontinued treatment because of adverse events, respectively. CONCLUSION Evidence from JCOG0905 does not support the addition of IF for patients with PrRsp.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Musculoskeletal Oncology, NHO Hokkaido Cancer Center, Sapporo, Japan.
- Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
- Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Orthopaedic Surgery, Faculty of Medicine, Okayama University, Okayama, Japan.
- Orthopaedic Surgery, Chiba Cancer Center, Chiba, Japan.
- Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Hiroaki Hiraga, Toshiyuki Kunisada, Makoto Endo, Akihito Nagano, Shinichirou Yoshida, Kunihiro Asanuma, Taisuke Furuta, Robert Nakayama, Toshihiro Akisue, Hideki Nishimura, Koji Hiraoka, Masanobu Takeyama, Makoto Emori, Satoshi Tsukushi, Hiroshi Hatano, Hiroyuki Kawashima, Kazuhiro Tanaka, Tomoko Kataoka, Toshifumi Ozaki
Zitieren
APA
Hiraga, H., Machida, R., Kawai, A., Kunisada, T., Yonemoto, T., Endo, M., Nishida, Y., Nagano, A., Ae, K., Yoshida, S., Asanuma, K., Toguchida, J., Furuta, T., Nakayama, R., Akisue, T., Hiruma, T., Morii, T., Nishimura, H., Hiraoka, K., …, & Ozaki, T. (2025). Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial. Journal of Clinical Oncology, 43(16), 1886-1897. https://doi.org/10.1200/jco-24-01281
Vancouver
Hiraga H, Machida R, Kawai A, Kunisada T, Yonemoto T, Endo M, et al. Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial. Journal of Clinical Oncology. 2025;43(16):1886-1897. doi:10.1200/jco-24-01281
BibTeX
@article{Hiraga2025,
author = {Hiraga, Hiroaki and Machida, Ryunosuke and Kawai, Akira and Kunisada, Toshiyuki and Yonemoto, Tsukasa and Endo, Makoto and Nishida, Yoshihiro and Nagano, Akihito and Ae, Keisuke and Yoshida, Shinichirou and Asanuma, Kunihiro and Toguchida, Junya and Furuta, Taisuke and Nakayama, Robert and Akisue, Toshihiro and Hiruma, Toru and Morii, Takeshi and Nishimura, Hideki and Hiraoka, Koji and Takeyama, Masanobu and Emori, Makoto and Tsukushi, Satoshi and Hatano, Hiroshi and Kawashima, Hiroyuki and Isu, Kazuo and Tanaka, Kazuhiro and Kataoka, Tomoko and Fukuda, Haruhiko and Iwamoto, Yukihide and Ozaki, Toshifumi},
title = {Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {16},
pages = {1886--1897},
doi = {10.1200/jco-24-01281}
}
EUVIMED